Eli Lilly and Company (NYSE:LLY) Trading 3.7% Higher After Analyst Upgrade

Eli Lilly and Company (NYSE:LLY)’s stock price shot up 3.7% during trading on Monday after Truist Financial raised their price target on the stock from $1,370.00 to $1,376.00. Truist Financial currently has a buy rating on the stock. Eli Lilly and Company traded as high as $1,231.94 and last traded at $1,230.00. Approximately 2,922,758 shares were traded during trading, a decline of 7% from the average session volume of 3,142,988 shares. The stock had previously closed at $1,185.71.

Several other equities research analysts have also recently weighed in on LLY. JPMorgan Chase & Co. increased their price objective on Eli Lilly and Company from $1,300.00 to $1,400.00 and gave the stock an “overweight” rating in a report on Tuesday, July 7th. Sanford C. Bernstein lifted their price target on shares of Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the company an “outperform” rating in a report on Tuesday, July 14th. Cantor Fitzgerald upped their price objective on shares of Eli Lilly and Company from $1,350.00 to $1,410.00 and gave the stock an “overweight” rating in a report on Thursday. Leerink Partners raised their target price on shares of Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the stock an “outperform” rating in a research report on Thursday, June 25th. Finally, Bank of America boosted their price target on shares of Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the company a “buy” rating in a research report on Friday, July 10th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Eli Lilly and Company has a consensus rating of “Moderate Buy” and an average target price of $1,292.18.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Blowout Q2 results and raised outlook: Lilly reported $22.97 billion in second-quarter revenue, up 47.7% year over year and above the $20.82 billion consensus estimate. Adjusted earnings of $8.38 per share also exceeded expectations by $1.98. Management raised its full-year targets, reinforcing expectations for sustained growth from Mounjaro and Zepbound. Why Did Eli Lilly Jump After Its Latest Quarterly Report?
• Positive Sentiment: Oral obesity drug could expand the market: Investor optimism is also focused on Lilly’s next-generation obesity pill. Broader prescribing access and potential insurance coverage could make an oral treatment an important growth catalyst alongside the company’s injectable GLP-1 medicines. Eli Lilly Stock’s Next Climb Runs Through a Pill
• Positive Sentiment: Competitive position in obesity drugs: Analysts continue to view Lilly as a leading GLP-1 provider, with a deep pipeline and strong commercial momentum. A more cautious outlook for rival Novo Nordisk highlights Lilly’s current competitive advantage. Novo Nordisk Stock Plunges Amid Eli Lilly Rivalry
• Positive Sentiment: Pipeline diversification: Lilly’s olomorasib received FDA Breakthrough Therapy designation for certain advanced pancreatic cancer patients, while a collaboration will evaluate the drug in lung cancer. The developments support efforts to broaden growth beyond diabetes and obesity. Eli Lilly Gains FDA Breakthrough Nod
• Neutral Sentiment: Lilly participated in Remedium Bio’s $10 million Series A financing, offering potential long-term pipeline exposure but little immediate earnings impact. Lifespan Vision Ventures Leads Remedium Bio Financing
• Negative Sentiment: The stock is trading near its 52-week high at a premium valuation, leaving less room for execution disappointments, regulatory setbacks or intensifying competition in the GLP-1 market.

Institutional Investors Weigh In On Eli Lilly and Company

Several hedge funds have recently bought and sold shares of LLY. Osbon Capital Management LLC bought a new position in Eli Lilly and Company during the 4th quarter valued at approximately $25,000. Basso Capital Management L.P. bought a new position in shares of Eli Lilly and Company during the fourth quarter valued at $30,000. Maseco LLP raised its position in shares of Eli Lilly and Company by 466.7% in the 1st quarter. Maseco LLP now owns 34 shares of the company’s stock worth $31,000 after purchasing an additional 28 shares during the last quarter. E Fund Management Hong Kong Co. Ltd. boosted its stake in Eli Lilly and Company by 342.9% in the 4th quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock worth $32,000 after purchasing an additional 24 shares in the last quarter. Finally, Aventus Investment Advisors Inc. grew its position in Eli Lilly and Company by 270.0% during the 1st quarter. Aventus Investment Advisors Inc. now owns 37 shares of the company’s stock valued at $34,000 after purchasing an additional 27 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

The company has a current ratio of 1.35, a quick ratio of 1.00 and a debt-to-equity ratio of 1.41. The firm has a market capitalization of $1.16 trillion, a P/E ratio of 41.28, a price-to-earnings-growth ratio of 1.38 and a beta of 0.51. The business’s 50 day simple moving average is $1,159.38 and its two-hundred day simple moving average is $1,047.62.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.40 by $1.98. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The firm had revenue of $22.97 billion for the quarter, compared to the consensus estimate of $20.82 billion. During the same quarter in the prior year, the firm posted $6.31 earnings per share. The business’s revenue was up 47.7% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Sell-side analysts anticipate that Eli Lilly and Company will post 36.77 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be given a $1.73 dividend. The ex-dividend date of this dividend is Friday, August 14th. This represents a $6.92 annualized dividend and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is 23.22%.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.